Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone
- 1 November 2004
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 94 (10) , 1329-1332
- https://doi.org/10.1016/j.amjcard.2004.07.128
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Long-term Intermittent Dobutamine Infusion, Combined With Oral Amiodarone for End-Stage Heart FailureChest, 2004
- Efficacy of amiodarone treatment on cardiac symptom, function, and sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with β-blocker therapyJournal of Nuclear Cardiology, 2004
- Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: A prospective, randomized trialAmerican Heart Journal, 2003
- Long-term intermittent dobutamine infusion combined with oral amiodarone improves the survival of patients with severe congestive heart failure.Chest, 2001
- LevosimendanDrugs, 2001
- Gi-Dependent Localization of β2-Adrenergic Receptor Signaling to L-Type Ca2+ ChannelsBiophysical Journal, 2000
- Antiadrenergic effect of chronic amiodarone therapy in human heart failureJournal of the American College of Cardiology, 1999
- Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendanJournal of Molecular and Cellular Cardiology, 1995
- Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study.Journal of Biological Chemistry, 1994